An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 20 May 2014
At a glance
- Drugs Paliperidone (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Pharmaceutica
- 01 Mar 2013 Actual initiation date changed from May 2007 to Jun 2007 as reported by ClinicalTrials.gov.
- 27 Aug 2012 Planned number of patients changed from 1104 to NULL.
- 17 Aug 2012 New trial record